CTOs on the Move

HealthiVibe

www.healthivibe.com

 
HealthiVibe captures patient insights around clinical trial design and patient-centered initiatives. We believe the patient voice is critical in healthcare.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Dan Kett
Director Information Technology Services Profile

Similar Companies

Unique Pharmaceuticals

Unique Pharmaceuticals is a Temple, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Caron Products and Services

Caron Products is a provider of incubators & chambers for cell growth and product environmental testing in biological research, scale-up culture, and drug and biological QA/QC testing. Caron`s products are integral to workflows ranging from cell & gene therapy to medical device manufacturing. Caron`s expanding resources, with manufacturing facilities in both the USA and Europe, and a worldwide network of sales and service personnel aligns with the needs of the global biomedical industry.

Bloomios

Bloomios is a U.S. based leading hemp and nutraceutical GMP manufacturer specializing in product development, formulation, packaging, and design. They provide white label and private label services for businesses looking to expand into the hemp industry.

Integrated Viral Protection

World-Leading Biodefense Indoor Air Protection Systemâ„¢ Scientifically proven to destroy COVID-19 (99.999%) and Anthrax spores (99.98%) instantaneously in a single pass. Learn More Scientifically proven to Kill Sars-CoV-2, the virus that causes COVID-19...

Respira Therapeutics

Respira Therapeutics, Inc., founded in 2010 with offices in Albuquerque, New Mexico, is a development stage inhaled pharmaceutical development company focused on commercializing its "best in class", high efficiency AOS-DPI, dry powder inhaler (DPI) drug delivery technology to deliver RT234, a proprietary inhaled formulation of an off patent oral drug via the lung to treatment of multiple orphan indications in the fields of pulmonary hypertension and other diseases. Investors in Respira include Cottonwood Technology Fund and Sun Mountain Capital and individual investors. To date Respira has performed extensive testing demonstrating its advanced AOS-DPI prototypes can deliver 2-3X more drug to the lung than commercially available DPI technologies. Respira is planning proof of concept clinical trials of an inhaled formulation of RT234 in pulmonary arterial hypertension patients in the near future.